488results about How to "Dissolution rate is fast" patented technology

The invention relates to a rapidly-dissolving and stabile montelukast oral solid preparation and a preparation method thereof, wherein the preparation uses montelukast as a raw material drug, is added with a diluents, a disintegrating agent, an additive, an adhesive and a lubricant as auxiliary materials, and uses a pharmaceutically acceptable preparation technology. The preparation and the preparation technology can raises a dissolving speed of the oral preparation, enables the oral preparation to substantially raise the dissolving speed in a dissolving mediums of pH1.0 and pH 4.5, and can raises the medicament stability.

A water-soluble coenzyme Q10 composition for treating cardiovascular disease, hepatitis and hypoimmunocompetence is proportionally prepared from coenzyme Q10, gamma-cyclodextrin, alditol and disintegrant through high-speed stirring in water or ultrasonic oscillating, high-pressure homogenizing, freeze-drying, and granulating.

The invention provides a crystal form, preparing method and application of Olaparib. According to the Olaparib with the new crystal form, CuKa radiation is adopted, powder X-ray diffraction represented by 2 theta angle has diffraction peaks at 22.9+/-0.5, 23.4+/-0.5, 21.0+/-0.5, 17.1+/-0.5, 17.3+/-0.5, 14.2+/-0.5, 15.0+/-0.5, 13.5+/-0.5, 18.6+/-0.5, 20.6+/-0.5, 10.2+/-0.5, 20.3+/-0.5, 21.9+/-0.5, 25.8+/-0.5 and 26.5+/-0.5. The granularity D50 of the Olaparib with the crystal form is 2.45 microns which is quite small, so that dissolving-out speed is high when the Olaparib serves as a preparation, and drug efficacy of a product is improved. Furthermore, the preparing method is simple, and the performance of the obtained Olaparib with the crystal form is stable.

The invention belongs to the field of medicaments and in particular relates to tablets containing mosapride citrate and a preparation method thereof. Because the mosapride citrate is almost insoluble, defects of slow dissolution and low in-vitro and in-vivo bioavailability are present in the mosapride citrate tablets prepared by the common method. In order to improve the dissolution and bioavailability of the mosapride citrate, the invention provides dispersible tablets containing the mosapride citrate and a preparation method thereof. The prepared mosapride citrate dispersible tablets have high dissolution speed and low dissolution difference. The accumulated dissolution in five minutes is close to 100 percent, and the dispersible tablets are almost dissolved completely.

The invention provides a celecoxib solid composition with high dissolution, a preparation method and an application. The amorphous composition of celecoxib is obtained by dissolving the celecoxib into one or more pharmaceutically acceptable solvents and adsorbing and drying with pharmaceutically acceptable auxiliary materials. The composition can be further prepared into various solid preparation forms such as tablets, capsules and granules according to the actual requirement. Through the prepared celecoxib composition and preparations thereof, the dissolution of the celecoxib can be greatly improved, and the defects of low dissolution and low bioavailability of the celecoxib are overcome.

The invention relates to an ellagic acid supramolecular combination and a preparation method. The substance is an anti-oxidant and has the anti-cancer effect, and the ellagic acid supramolecular combination belongs to the technical field of drugs and health care products. The ellagic acid supramolecular combination is composed of raw materials according to the following weight ratio that ellagic acid: cyclodextrin: emulsifier is equal to 1: (1-50): (0-10). The ellagic acid, the cyclodextrin and the emulsifier are added into a colloid mill, and the ellagic acid supramolecular combination is prepared by grinding and drying. The combination has the advantages of higher solubility, high dissolution rate, good stability and higher relative bioavailability.

The present invention provides a preparation method of bamboo pulp, belonging to the field of chemical fiber technology. Said method includes the following steps: obliquely cutting bamboo strip material into the form of horseshoe, the chip cross-section spacing distance is 20-40 mm, then prehydrolyzing the prepared bamboo strip, adding alkali and cooking, removing sand, making one-stage or two-stage bleaching treatment, making the bleached pulp material undergo the processes of acid treatment, concentration and pulping so as to obtain the invented bamboo pulp. Said bamboo pulp can be used for producing viscose fibre.

The invention relates to a coenzyme Q10 combination and a preparation method thereof and provides a water-soluble coenzyme Q10 combination, which contains the following raw materials in parts by weight: 5-15 parts of coenzyme Q10, 10-120 parts of water-soluble carrier and 0.5-40 parts of emulsifier; the water-soluble carrier is one or more of maltodextrin, CMC, purity gum, soluble starch, lactose, fructose, sorbierite, mannite, Arabic gum, carrageenan, microcrystalline cellulose and sodium carboxymethyl starch; and the emulsifier is non-ionic surfactant. The invention also provides the preparation method of the water-soluble coenzyme Q10 combination. Fat-soluble coenzyme Q10, the water-soluble carrier and the amphoteric emulsifier are mixed and prepared into the water-soluble coenzyme Q10 combination, and the method synthesizes the advantages of an inclusion technique and a solid dispersion technique and solves the problems that the fat-soluble coenzyme Q10 is difficult to dissolve in water and has low bioavailability, and a number of experiments prove that the water-soluble coenzyme Q10 combination has good water solubility, fast dissolution rate, good stability and high content of effective substances.

The invention discloses Tofacitinib citrate tablets composed of Tofacitinib citrate and pharmaceutically acceptable auxiliary materials. The auxiliary materials comprise filler, disintegrating agent, flow aid and coating materials. The filler is microcrystalline cellulose lactose premix with the model of Celactose80, and the weight ratio of the Tofacitinib citrate to the microcrystalline cellulose lactose premix with the model of Celactose80 is 1:5-25. The invention further discloses a preparation method. The Tofacitinib citrate tablets has high content uniformity and have the advantages of being high in dissolving-out speed, stable in chemical property and the like.

The invention belongs to the technical field of medicines, and particularly relates to an azilsartan tablet. The azilsartan tablet contains azilsartan, hydroxy propyl cellulose and fumed silica, and is prepared by the following steps: dissolving the azilsartan and the hydroxy propyl cellulose in diethylene glycol monoethyl ether, adding the fumed silica to adsorb, uniformly mixing with pharmaceutically acceptable auxiliary materials and pressing by a direct tableting process. Compared with the prior art, the azilsartan tablet is high in drug dissolution speed and simple in process.

The invention provides an acerola cherry preparation which is characterized by comprising 1-50 parts by mass of acerola cherry powder, 20-96 parts by mass of diluent, 2-15 parts by mass of synthetic vitamin C and 0.5-15 parts by mass of additives. The preparation method comprises the following steps of: pulping acerola cherry fruits after pretreatment, adding deastringent liquid into the obtained acerola cherry pulp to agitate, colloid-milling, homogenizing and filtering the mixture to obtain first filter liquid for later use, adding pectinase and cellulose into the obtained first filter residue for enzymolysis treatment, and colloid-milling, homogenizing and filtering the mixture once again to obtain second filter liquid, wherein the deastringent liquid is mixed water solution of citric acid and sodium chloride; and mixing the first filter liquid and the second filter liquid, homogenizing the mixture, carrying out vacuum concentration to obtain concentrated liquid, adding auxiliary materials comprising resistant starch and isomaltooligosaccharide into the concentrated liquid, homogenizing the mixture, and then carrying out vacuum drying to obtain the acerola cherry powder. The acerola cherry preparation provided by the invention has quick vitamin C dissolution speed and high bioavailability.

The invention relates to an Azilsartan tablet and a preparation method thereof. The Azilsartan tablet contains micronized Azilsartan, lactose anhydrous 21AN, lactose anhydrous 24AN, a disintegrating agent, and a lubricant, and is prepared by pressing through adopting tabletting technology. Compared with the prior art, the Azilsartan tablet is fast in dissolving speed, simple in technology, and an acceleration test result shows that the prepared Azilsartan tablet has good stability.

A provided (-)-pantoprazole sodium enteric coated tablet consists of a tablet core containing (-)-pantoprazole sodium, a separation layer and an enteric layer, the increased weight of the separation layer accounts for 2-9%, and the increased weight of the enteric layer accounts for 7-15%. In dissolution tests using a system with pH of 5.5 or more, 85% or more of the main drug is dissolved in 30 min. The prepared (-)-pantoprazole sodium enteric coated tablet is an oral preparation with stable quality and high bioavailability.

The invention relates to solid dispersion as well as a preparation method and an application thereof. The solid dispersion is prepared from indissolvable drugs, a surfactant and a water-soluble polymer material with a spray drying method after mixing and heating dissolution, wherein the surfactant is selected from at least one of sodium dodecyl sulfate, poloxamer, tween, alpha-tocopherol, succinate, polyethylene glycol, sodium cholate and polyethylene glycol/vinyl caprolactam/vinyl acetate copolymer; the water-soluble polymer material is selected from at least one of povidone, copovidone, hydroxypropyl methylcellulose and polyethylene glycol. An organic solvent is not required when the solid dispersion is prepared with the spray drying method, and the problem of organic solvent residues is solved. By means of the solid dispersion, the dissolvability of the indissolvable drugs is increased, the dissolution speed and the dissolubility are remarkably increased, and the bioavailability of the indissolvable drugs is improved.

The invention discloses an apixaban tablet and a preparation method thereof, and belongs to the technical field of medicines. The apixaban tablet consists of a tablet core and a coating, wherein the tablet core is composed of apixaban, a fiber-lactose compound, crosslinked carboxy methyl cellulose, lauryl sodium sulfate and magnesium stearate; various components in the tablet core are controlled within limited dosage ranges and a mutual synergistic effect is achieved, so that the dosage of the cross-linked sodium carboxymethyl cellulose as a disintegrating agent is reduced and the dissolution rate of the apixaban tablet is improved; therefore, the average dissolution rate within 10min is more than 90%, the dissolution rate is slightly affected by illumination, temperature and humidity, the performance is stable, and the apixaban tablet is low in contents of impurities. According to the preparation method of the apixaban tablet disclosed by the invention, the tablet core is prepared by a way of directly tabletting a powdery mixture, so that a granulation process is avoided, operation is simple and convenient, and the technological process is simple; and the apixaban, as a crude drug, is subjected to micronization treatment before the mixed powder is prepared, so that the dissolution rate of the apixaban tablet is accelerated.

The invention provides a protopanaxadiol solid dispersion and its preparing method, wherein the weight ratio of the protopanaxadiol and carrier material is 1:1-50, and protopanaxadiol solid dispersion can be prepared through melting method, solvent method, solvent-melting method, grinding method, spray-drying method or freeze drying method. The preparation can be made into the dosage forms of capsules, tablets, suppositories and drop pills.

The invention relates to albendazol dispersible tablets and a preparation method thereof. The albendazol dispersible tablets comprise, by weight ratio, 200g of albendazol, 50-160g of disintegrant, 18-118g of diluent, 2-12g of surfactant, 6-16g of sweetener, 3-12g of glidant, and 1-4g of lubricant. Bioavailability of the albendazol dispersible tablets made from the proper accessories is improved evidently, and curative effect of the albendazol dispersible tablets is improved. The albendazol dispersible tablets are available to take in multiple ways, and different patients can take the albendazol dispersible tablets in different ways, so that patient compliance is improved. Practice shows that preparation technology of the albendazol dispersible tablets is high in production mechanization level, simple to operate, high in production efficiency and low in cost. The dispersible tablets produced by the preparation technology have the advantages of high dispersing uniformity, short disintegrating time, and fast dissolution, and the product quality completely meets the requirements.

The invention belongs to the technical field of drugs and in particular relates to a rivaroxaban tablet. The rivaroxaban tablet contains rivaroxaban, hydroxypropyl cellulose and fumed silica and is prepared by dissolving rivaroxaban and hydroxypropyl cellulose in diethylene glycol monoethyl ether, adding fumed silica for adsorption, then mixing the materials with pharmaceutically acceptable auxiliary materials uniformly and pressing the mixture by adopting a direct tabletting process. Compared with the prior art, the rivaroxaban tablet is high in drug dissolution speed and simple in process and dispenses with addition of surfactants and micronization treatment.

The invention provides a beta-cyclodextrin / amoxicillin inclusion compound medicinal composition which comprises amoxicillin and beta cyclodextrin by the weight ratio of 1:2.5-1:5. In a preferred embodiment, the composition also comprises clavulanate potassium, wherein the mass ratio of amoxicillin and clavulanate potassium is 14:1-2:1, the supplementary materials are selected from crystalline cellulose, maize starch, citric acid, talcum powder, sodium carboxymethylstarch, stearic acid, calcium stearate, magnesium stearate, amylopectin, lactose, mannitol, crosslinked povidone, talcum powder, polyethylene glycol 4000, and low substituted methylcellulose propylene glycol ether. The invention also discloses the preparing process.

The invention discloses a nimodipine capsule with high dissolution and semi-solid composition as content and a preparation method thereof, and belongs to the pharmaceutical preparation field. The method comprises the following steps of mixing micronized nimodipine and a hydrophilic carrier, preparing into solid dispersion by melting extrusion method, cooling, pulverizing, mixing with semi-solid matrix, surfactant, melting point regulator under heating, and filling the content into hard capsule with a capsule filling machine. The invention combines the melting extrusion technique and semi-solid filling hard capsule technique, and after the prepared novel nimodipine capsule is administered into human body, the nimodipine quickly diffuses in molecular form and saturates metabolic enzymes, so as to improve bioavailability. The inventive nimodipine capsule solves the low dissolution and low utilization ratio problems of prior nimodipine preparation; and has the advantages of high dissolution, good stability, simple preparation method, and applicability to industrial production.

The invention provides a stable taste-masking levocetirizine medicine composition and a preparation method thereof. The medicine composition comprises levocetirizine, a taste masking agent and a stabilizer, the levocetirizine is levocetirizine hydrochloride, the taste masking agent is beta-cyclodextrin or a derivative thereof, and the stabilizer is sodium citrate. Other pharmaceutically acceptable auxiliary materials are selectively added in the medicine composition, the medicine composition can be further prepared into granules, orally disintegrating tablets and chewable tablets, tastes good, is quick in absorption, stable in quality, simple and feasible in preparation process, and can be produced in batches by using the conventional pharmaceutical equipment, and the related medicinal auxiliary materials are easy to purchase and low in cost.

The invention relates to a process for preparing gelatin, in particular to a process for producing high-viscosity cowhide alkaline gelatin by a batch and alkaline (BATALK) method. The process comprises pretreatment, rubber extraction, filtration, ion exchange, concentration, high temperature sterilization, drying, crushing, mixing, metal detection and formation of a finished product. The process is characterized in that: the pretreatment process is the BATALK method. By the process, the consumption of water and the consumption of sulfur acid can be reduced; and the gelatin obtained by the process has high viscosity.